Your browser doesn't support javascript.
loading
Metabonomic study of metformin in type II diabetic rats / 中国药理学通报
Chinese Pharmacological Bulletin ; (12): 1212-1220, 2019.
Article in Zh | WPRIM | ID: wpr-857144
Responsible library: WPRO
ABSTRACT
Aim To study the mechanism of metformin in the treatment of type 2 diabetic melitus (T2DM) rats. Methods Rats were randomly divided into normal group, model group and metformin group with 10 rats in each group. Four weeks after induction with HFSD, 35 mg 'kg-1 STZ was injected intramuscularly, and the experiment was completed after 8 weeks of administration. UPLC/ESI-TOF-MS was used to study the effects of metformin on metabolites in serum of T2DM rats, and qPCR was used to find its target. Results Compared with normal group, the body weight, pancreatic index and insulin level in model group decreased significantly (P < 0. 05) , liver index, GLU, TC, TG and FFA levels increased significantly (P < 0.01), OGTT was significantly impaired, while met-formin could significantly increase body weight, pancreatic index and insulin level (P <0. 05) , reduce liver index, GLU, TC, TG and FFA levels (P < 0. 05) , and improve OGTT. After metahonomics, 17 biomark-ers were obtained. After verification, metformin was found to regulate the synthesis and metabolism of cholesterol, fatty acids, bile acids and phospholipids. Conclusions Metformin can improve the lipid metabolism disorder of T2DM by regulating the synthesis and metabolism of cholesterol, fatty acids, bile acids and phospholipids.
Key words
Full text: 1 Index: WPRIM Language: Zh Journal: Chinese Pharmacological Bulletin Year: 2019 Type: Article
Full text: 1 Index: WPRIM Language: Zh Journal: Chinese Pharmacological Bulletin Year: 2019 Type: Article